Schizophrenia and type 2 diabetes are linked, but GLP-1s could help manage the risks
Treatment with glucagon-like peptide-1 receptor agonists (GLP-1s) was associated with lower risks of psychiatric hospitalization and psychiatric emergency department visits in people with both schizophrenia and type 2 diabetes (T2D), compared with no GLP-1 treatment or treatment with newer diabetes medications, according to new research published in The Lancet Psychiatry.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
